Current Report Filing (8-k)
January 25 2023 - 09:08AM
Edgar (US Regulatory)
0001711754 false 0001711754 2023-01-25
2023-01-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported):
January 25, 2023
|
INMUNE BIO INC. |
| (Exact name of
registrant as specified in charter) |
|
Nevada |
|
001-38793 |
|
47-5205835 |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of incorporation) |
|
|
|
Identification No.) |
225 NE Mizner Boulevard,
Suite 640,
Boca Raton,
FL
33432
(Address of Principal Executive Offices) (Zip Code)
(858)964-3720
(Registrant’s Telephone Number, Including Area Code)
Not
Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mart if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
INMB |
|
The
NASDAQ Stock Market LLC |
Item 8.01. Other Events.
On January 25, 2023, INmune Bio Inc. (the “Company”) issued a press
release announcing pre-clinical data that supports an approach to
treating Duchenne Muscular Dystrophy to decrease muscle damage and
significantly increase muscle regeneration. A copy of this press
release is attached herewith as Exhibit 99.1.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Date: January 25, 2023 |
INMUNE BIO
INC. |
| |
|
| |
By: |
/s/ David Moss |
| |
|
David Moss |
| |
|
Chief Financial Officer |
2
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From May 2023 to Jun 2023
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2022 to Jun 2023
